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Splicing misregulation of SCN5A contributes to
cardiac-conduction delay and heart arrhythmia in
myotonic dystrophy
Fernande Freyermuth1,*,w, Fre´de´rique Rau2,*, Yosuke Kokunai3, Thomas Linke4, Chantal Sellier1, Masayuki Nakamori3,
Yoshihiro Kino5, Ludovic Arandel2, Arnaud Jollet2, Christelle Thibault1, Muriel Philipps1, Serge Vicaire1, Bernard Jost1,
Bjarne Udd6,7,8, John W. Day9, Denis Duboc10, Karim Wahbi10, Tsuyoshi Matsumura11, Harutoshi Fujimura11,
Hideki Mochizuki3, Franc¸ois Deryckere12, Takashi Kimura13, Nobuyuki Nukina14, Shoichi Ishiura15, Vincent Lacroix16,
Amandine Campan-Fournier17, Vincent Navratil18, Emilie Chautard19, Didier Auboeuf19, Minoru Horie20, Keiji Imoto21,
Kuang-Yung Lee22, Maurice S. Swanson23, Adolfo Lopez de Munain24, Shin Inada25, Hideki Itoh20, Kazuo Nakazawa25,
Takashi Ashihara20, Eric Wang23, Thomas Zimmer4, Denis Furling2, Masanori P. Takahashi3 & Nicolas Charlet-Berguerand1
Myotonic dystrophy (DM) is caused by the expression of mutant RNAs containing expanded
CUG repeats that sequester muscleblind-like (MBNL) proteins, leading to alternative splicing
changes. Cardiac alterations, characterized by conduction delays and arrhythmia, are the second
most common cause of death in DM. Using RNA sequencing, here we identify novel splicing
alterations in DM heart samples, including a switch from adult exon 6B towards fetal exon 6A in
the cardiac sodium channel, SCN5A. We ﬁnd that MBNL1 regulates alternative splicing of SCN5A
mRNA and that the splicing variant of SCN5A produced in DM presents a reduced excitability
compared with the control adult isoform. Importantly, reproducing splicing alteration of Scn5a in
mice is sufﬁcient to promote heart arrhythmia and cardiac-conduction delay, two predominant
features of myotonic dystrophy. In conclusion, misregulation of the alternative splicing of SCN5A
may contribute to a subset of the cardiac dysfunctions observed in myotonic dystrophy.
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M
yotonic dystrophy (DM), the most common adult-onset
muscular dystrophy, includes two genetically distinct
forms. DM of type 1 (DM1) and its severe congenital
form (CDM1) are caused by an expansion of CTG repeats in the
30-untranslated region (UTR) of the DMPK gene1–3. In contrast,
DM of type 2 (DM2) is caused by an expansion of CCTG repeats
within the ﬁrst intron of the CNBP (also known as ZNF9) gene4.
The pathogenesis of DM involves a RNA gain-of-function
mechanism caused by expression of mutant RNAs containing
hundred to thousands of CUG or CCUG repeats that interfere
with the splicing of other pre-mRNAs through dysfunction
of two classes of RNA-binding proteins. MBNL proteins
(MBNL1, MBNL2 and MBNL3) are sequestered within nuclear
RNA foci formed by expanded CUG and CCUG repeats5,6,
whereas expression and phosphorylation of CUG-binding
protein 1 (CUGBP1, encoded by the CELF1 gene) are increased
in DM1 heart samples7. MBNL and CUGBP1 proteins regulate
alternative splicing, and alterations of their functional levels in
myotonic dystrophic tissues results in reversion to fetal
splicing patterns for several mRNAs, such as the insulin
receptor (INSR) (ref. 8), the muscle chloride channel (CLCN1)
(refs 9,10), dystrophin (DMD) (refs 11,12) and key components
of the skeletal muscle excitation–contraction coupling
process, including amphiphysin2 (BIN1) (ref. 13), ryanodine
receptor 1 (RYR1) (ref. 14), sarcoplasmic/endoplasmic reticulum
Ca2þ -ATPase SERCA1 (ATP2A1) (ref. 14) and the muscle
calcium channel CaV1.1 (CACNA1S) (ref. 15). Misregulation of
the alternative splicing of the insulin receptor INSR, CLCN1 and
DMD mRNAs are associated with the insulin resistance8,
myotonia9,10,16 and dystrophic process12, respectively, while
alterations of the alternative splicing of BIN1, RYR1, ATP2A1
and CACNA1S may contribute to the skeletal muscle weakness
observed in DM13–15.
In contrast, the molecular mechanisms underlying the cardiac
defects, which affect 80% of individuals with DM and represent
the second most common cause of death in this disease17,18, are
yet to be deﬁned. Cardiac involvements in DM are characterized
by cardiac-conduction delay that may result in fatal atrio-
ventricular block, and by atrial or ventricular tachycardia17,18.
Electrocardiography (ECG) analyses in DM patients indicate
prolonged conduction time from the sinoatrial node to the
ventricles (PR interval) and elongated ventricular depolarization
(QRS duration). Interestingly, cardiac dysfunctions in DM are
reminiscent in some aspect to an alteration of the cardiac
sodium current. The a-subunit of the cardiac voltage-gated Naþ
channel, Nav1.5, is encoded by the SCN5A gene and plays a key
role in the excitability of cardiomyocytes and for rapid
propagation of the impulse through the cardiac-conduction
system. Mutations in SCN5A lead to a variety of arrhythmic
disorders, including long QT3, progressive and non-progressive
cardiac-conduction disease (also known as Lev-Lene`gre disease),
atrial ﬁbrillation, sick sinus syndrome, Brugada syndrome and
numerous overlapping syndromes19–21.
Using transcriptomic approaches, we identiﬁed various novel
splicing changes in heart samples of DM1 individuals. Analysis of
the RNA motifs enriched in the vicinity of these misregulated
exons indicates that sequestration of the MBNL proteins is
probably the main cause of splicing misregulation in heart of
individuals with DM. Among these novel splicing alterations,
we focused on misregulation of alternative splicing of the
SCN5A pre-mRNA. This splicing alteration results in expression
of a fetal isoform of SCN5A with altered electrophysiological
properties. Of importance, we demonstrate that reproducing
the splicing alteration of Scn5a in mouse is sufﬁcient to cause
heart arrhythmia and cardiac-conduction delay with elevated PR
interval, which are key characteristics of the heart alterations
observed in DM. These results suggest that altered splicing of
SCN5A mRNA may participate to the electrical cardiac
abnormalities observed in DM.
Results
Identiﬁcation of splicing changes in DM heart samples. To
determine novel splicing abnormalities in DM heart samples, we
ﬁrst used whole-genome microarrays (GeneChip Human Exon
1.0 ST array) on polyadenylated RNA extracted from left ventricle
samples of three adult DM1 patients compared with three age-
matched control individuals. Bioinformatic analyses predicted
signiﬁcant (Fold Change Z2, Sudent t-test, P value r0.01)
changes in the splicing of 24 exons between control and DM1
samples (Supplementary Table 1), including a misregulation of
the alternative splicing of the SCN5A pre-mRNA. To extend this
analysis, we performed paired-end RNA sequencing (RNA-seq)
on the same DM1 and control heart samples, yielding 1,611
million of mapped 100 bp reads. DESeq and Cuffdiff were then
applied to estimate differential gene expression and over or
under-expressed mRNAs were selected by using the Benjamini
and Hochberg adjusted P values (false discovery rate (FDR)
r0.1). A total of 9 and 19 upregulated genes were predicted
differentially expressed with DESeq and Cuffdiff, respectively,
but none were conﬁrmed by quantitative real-time RT-qPCR
analyses. This low number of differentially expressed mRNAs
suggests that cardiac pathology in DM is not associated with
drastic modiﬁcations of gene expression levels. In contrast,
DEXSeq (ref. 22), which tests differential exon usage between two
conditions, predicted 134 signiﬁcant (Log2 Fold Change Z1.2,
FDR r0.1) alternative splicing changes between control and
DM1 heart samples (Supplementary Data 1). Similarly, MISO
(ref. 23) analysis, which computes the fraction of mRNA that
includes a given cassette alternative exon, predicted 259
signiﬁcant (DPSI Z0.3; Z-score Z1.2) alternative splicing
changes between control and DM1 heart samples (Fig. 1a and
Supplementary Data 2), including a robust misregulation of the
alternative splicing of SCN5A (Fig. 1b). MISO and DEXSeq pre-
dictions overlapped, but with some exceptions, such as the
skipping of the consecutive exons 18, 19 and 20 of CAMK2B
predicted by DEXSeq but not by MISO; or the shift of SCN5A
exon 6B towards exon 6A identiﬁed by MISO but not by DEXSeq.
These differences are inherent to their computation models, since
MISO does not detect alterations of successive exons and DEXSeq
does not identify mutually exclusive exons, highlighting that
MISO and DEXSeq are complementary bioinformatics
approaches. Next, we tested by PCR with reverse transcription
(RT–PCR) forty candidate mRNAs having the highest probability
of misregulation in DEXSeq and/or MISO analyses. We validated
splicing alterations for 32 of them, including some that have been
identiﬁed in previous studies (TNNT2, TNNT3, ABLIM1, LDB3,
MBNL1, CAMK2B, MAPT and so on)24–26, and 20 others that
represent, to the best of our knowledge, novel alterations of
alternative splicing (ADD3, GOLGA4, CRTC2, ARHGEF10L,
ANK3, DCLK2, EPN2, UNC13B, TECR, ARVCF, SOCS7, CELF1
and so on) in DM1 heart samples (Fig. 1c). Of interest, some of
these splicing alterations may be of pathological consequence
in DM. For example, knockout of the Socs7 gene in mouse results
in insulin resistance27. Whether the splicing misregulation of
SOCS7 in DM contributes to insulin resistance remains to be
tested. Also, RNA sequencing predicts an increased retention of
the penultimate intron of FCGRT, which encodes the Fc fragment
of the IgG receptor transporter a (FCRN) protein, involved in
IGG recycling28. Whether splicing alteration of FCGRT in DM is
responsible to the decreased level of IGG in blood of these
patients is an attractive hypothesis that remains to be tested.
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Finally, RNA sequencing predicts misregulation of the alternative
splicing of a cardiac-speciﬁc exon located in the 50-UTR of
CELF1, which encodes CUGBP1. Whether this alternative
splicing may contribute to the increase levels of CUGBP1
protein observed in DM1 hearts remains also to be evaluated.
Splicing altered in DM are enriched for MBNL-binding sites.
Mutants RNAs containing expanded CUG or CCUG repeats
interfere with the functional levels of CUGBP1 and MBNL
proteins. Earlier studies determined that MBNL proteins bind to
YGC RNA motifs (where Y is a pyrimidine)29–32, while CUGBP1
binds to UGU-enriched sequences33,34. To determine whether
these RNA motifs are indeed present in the vicinity of exons
misregulated in DM, we determined all 4-mer RNA motifs
enriched within, upstream or downstream of the exons predicted
as misregulated by MISO in DM1 heart samples, compared with
2,000 control exons (Fig. 2). Most RNA motifs signiﬁcantly
enriched (binomial test, P value o1.0 10 7) contained YGC
sequences, while none were found to contain UGU sequences.
Furthermore, YGC sequences were enriched upstream of
exons abnormally included in DM1, while YGC motifs were
enriched downstream of exons repressed in DM1. These results
matched the MBNL splicing regulatory map determined by CLIP
experiments, where binding of MBNL upstream of an exon tends
to inhibit exon inclusion whereas binding of MBNL downstream
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Figure 1 | Identiﬁcation of novel splicing misregulations in DM1 heart samples. (a) D-PSI versus Z-score plot of exon cassettes misregulations predicted
by MISO analysis. (b) Exons structure and coverage of RNA-seq reads across SCN5A exons 5–7 show increased inclusion of exon 6A and decreased
inclusion of exon 6B in heart samples of three DM1 patients (bottom, blue) versus three control samples (top, red). (c) Validation by
RT–PCR of RNA-seq predictions in human heart samples of normal adult individuals (CTL, black) versus adult DM1 patients (DM1, red). Molecular size
markers in bps are reported to the left of each RT–PCR gels. bp, base pair.
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of an exon generally stimulates exon inclusion35,36. In contrast,
we found no enriched motifs for other RNA-binding proteins,
including CUGBP1, rbFOX1, hnRNP H or Staufen. These results,
as well as previous data36–38, support a model in which titration
of MBNL proteins is the main cause of splicing change in DM1
heart, while misregulation of other RNA-binding proteins may
contribute to a subset of splicing alterations.
Splicing of SCN5A is misregulated in DM heart samples. Both
microarray and RNA-seq predicted misregulation of alternative
splicing of SCN5A pre-mRNA in DM1 heart samples. Splicing of
SCN5A is developmentally regulated, such that exon 6A is
included in fetal heart but rapidly replaced by exon 6B after
birth39. Consequently, SCN5A exon 6A is named as embryonic or
fetal, while exon 6B is known as adult. Exons 6A and 6B are
mutually exclusive exons encoding part of the voltage sensor,
segments 3 and 4 located in the domain I of the sodium channel
(Fig. 3a,b). These are key segments for the electrical activity of
the sodium channel, and inclusion of either fetal exon 6A or
adult exon 6B results in channel isoforms, named, respectively,
hNav1.5e and hNav1.5, with different electrophysiological
properties39–41. We conﬁrmed our microarray and RNA-seq
predictions by RT–PCR and found that adult SCN5A exon 6B is
partly replaced by its fetal exon 6A in heart samples of individuals
with DM, including adult DM1 and adult DM2 cases (Fig. 3c).
Note that to differentiate exon 6B from exon 6A that have
the exact same length of 92 bp, we took advantage of a BstbI
restriction site present only in exon 6A, which thus appears as a
BstbI-digested doublet band in Fig. 3c. These results are
consistent with the recent report of a splicing misregulation of
SCN5A in one DM1 heart sample42. Although splicing of SCN5A
is misregulated in DM1, we observed no correlation between the
percentage of SCN5A exon 6A inclusion and the increased
duration of the PR interval and only a very limited, if any,
correlation between misregulation of SCN5A exon 6A splicing
and alteration of the QRS duration in individuals with DM1
(R2 of 0.2 with six DM1 samples; Supplementary Fig. 1).
Misregulation of SCN5A splicing was speciﬁc to DM, as we did
not observe inclusion of exon 6A in heart samples from
individual affected with Duchenne muscular dystrophy (DMD),
amyotrophic lateral sclerosis (ALS) or dilated cardiomyopathy
(DCM) (Fig. 3d). Moreover, misregulation of splicing in DM1
was speciﬁc and not global, as we observed no splicing changes of
SCN5A alternative exon 18, of CACNA1C mutually exclusive
exons 8A and 8B, of KCNAB1 alternative exons 2 and 11, or of
KCNQ1 alternative exons 2 and 5 (Supplementary Fig. 2). Finally,
we observed no signiﬁcant alteration of the expression level of
SCN5A mRNA by quantitative real-time RT-qPCR (Fig. 3e).
Overall, these results indicate a speciﬁc misregulation of
alternative splicing of SCN5A resulting in expression of a fetal
form of this channel in adult DM heart. These results are
consistent with previous studies where alternative splicing
changes in DM resume a MBNL-dependent fetal splicing
pattern that persist in adult tissues26,37.
Alternative splicing of SCN5A is regulated by MBNL1. To
determine the mechanisms underlying misregulation of SCN5A
splicing, we ﬁrst determined its splicing pattern in cell models of
DM. Since SCN5A is expressed at low level in culture of immature
skeletal muscle cells, we investigated its splicing in primary
cultures of differentiated skeletal muscle cells originating from
muscle biopsies of control and DM1 individuals. RT–PCR
experiments determined a switch of exon 6B towards exon 6A
in DM1 muscle cells compared with control, reproducing the
splicing alteration observed in cardiac tissue (Fig. 4a). Of
technical interest, the basal level of exon 6A inclusion was
higher in muscle cell cultures than in adult heart samples
(compare Fig. 4a to Fig. 3c), which probably reﬂect the immature
aspect of cell cultures. Since mutant RNAs containing expanded
CUG or CCUG repeats interfere with alternative splicing through
titration of MBNL proteins, we tested whether MBNL1 regulates
SCN5A splicing. Reduction of MBNL1 expression through a
siRNA-mediated approach in human control primary muscle
cells mimicked the effect of CUG repeats and promoted a switch
from adult exon 6B towards fetal exon 6A (Fig. 4b). Western
blotting analysis conﬁrmed the successful depletion of MBNL1
expression (Supplementary Fig. 3A). Next, we assessed alternative
splicing of Scn5A in heart samples of Mbnl knockout mice43.
RT–PCR analysis shows that inclusion of the exon 6A of Scn5a is
increased in heart samples of mice with no Mbnl1 and reduced
level of Mbnl2 (Mbnl1 / , Mbnl2þ / )(Fig. 4c). The increased
inclusion of Scn5a exon 6A in Mbnl knockout mice is
signiﬁcant (Student t-test, P value r0.01) but rather mild,
probably reﬂecting difference in regulation of alternative splicing
between human and mouse or the compensatory effect of residual
Mbnl2 expression43. This hypothesis is consistent with the mild
splicing alteration of Scn5A observed in the sole Mbnl1 knockout
mice44. Overall, these results suggest that MBNL proteins regulate
the alternative splicing of SCN5A exons 6A and 6B. To determine
whether this regulation is direct or indirect, we constructed a
minigene containing exons 6A and 6B of SCN5A bordered by
their intronic regions. Expression of this construct in mouse
C2C12 myoblasts reproduced a fetal pattern with mainly
inclusion of exon 6A (Fig. 4d). Since inclusion of exon 6B was
repressed, reduction of Mbnl1 activity through siRNA or
expression of expanded CUG repeats had no further repressive
effect on exon 6B. In contrast, expression of MBNL1 promoted a
switch from fetal exon 6A towards adult exon 6B, while
CCCC (2×10–18)
CUGC (9×10–15)
UGCU (2×10–14)
CUAA (5×10–10)
UUGC (5×10–8)
CCUG (4×10–7)
UGCC (7×10–7)
UGCU (2×10–26)
GCUU (2×10–19)
CUGC (2×10–15)
UUGC (2×10–9)
CGCU (4×10–9)
GCUC (7×10–7)
GAAG (5.1 10–7)
CCGC (2×10–22)
CGCC (8×10–17)
CGCU (9×10–10)
UCGC (4×10–7)
GCGC (7×10–7)
CCCG (8×10–7)
CUGC (2×10–11)
UGCU (3×10–9)
GCUG (6×10–8)
Exons excluded in DM
Exons included in DM
Figure 2 | MBNL-binding motifs are enriched in vicinity of exons misregulated in DM1. Sequence and binomial test P values of 4-mer RNA motifs
enriched downstream, within and upstream of exons misregulated in DM1 heart samples. Sequences enriched in exons excluded in DM are indicated in red,
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expression or siRNA-mediated depletion of CUGBP1 had no
effect (Fig. 4d). Western blotting analysis conﬁrmed that siRNA
transfection efﬁciently reduced endogenous Mbnl1 or Cugbp1
expression (Supplementary Fig. 3B and C). Next, gel-shift assays
determined that recombinant puriﬁed GST-tagged MBNL1
bound to UGC RNA motifs located upstream of exon 6A
(Fig. 4e). Of interest, this UGC sequence is absent from the mouse
genome, which may explain the mild splicing alteration of Scn5A
observed in mice knockout for Mbnl proteins. Mutation of these
UGC motifs abolished MBNL1 binding (Fig. 4f), as well as the
regulatory effect of MBNL1 on a mutant SCN5A minigene
(Fig. 4g). Overall, these results establish that MBNL1 regulates
directly alternative splicing of SCN5A exons 6A/6B.
SCN5A splicing forms present different electrical properties.
SCN5A encodes Nav1.5, the main cardiac voltage-gated sodium
channel, and loss-of-function mutations in SCN5A lead to a
variety of arrhythmic disorders, which share some common
pathological features with DM. Furthermore, exons 6A and 6B
differ at seven amino acid positions, resulting in channel variants
with different electrophysiological properties39–41. To investigate
the consequences of the switch from SCN5A exon 6B towards
exon 6A observed in DM, we ﬁrst examined in Xenopus oocytes
the sodium currents generated by either hNav1.5e, the splice
variant of SCN5A containing the fetal exon 6A, or hNav1.5,
encoded by SCN5A containing the adult control exon 6B
(Fig. 5a and Supplementary Table 2). Injection of RNA
encoding hNav1.5e, which is the splicing isoform of SCN5A
found in DM, indicated a signiﬁcant reduction of the sodium
current amplitude of 45%, compared with hNav1.5, the normal
adult SCN5A exon 6B form (Fig. 5b,c). Since, the extent of
splicing misregulation varies among DM individuals, which
typically express a mix of SCN5A splicing forms containing either
exon 6A or exon 6B (cf. Fig. 3c), we analysed sodium currents
generated by a mix of both SCN5A isoforms (Fig. 5a). Injecting
Xenopus oocytes with an equimolar mix of RNA encoding each
channel, namely 50% of hNav1.5e (SCN5A containing fetal exon
6A) and 50% of hNav1.5 (SCN5A expressing adult exon 6B),
resulted in a reduction of 30% of the current amplitude compared
with the control hNav1.5 (Fig. 5b,c). Next, two-electrode voltage
clamp recording experiments revealed that the steady-state
activation of the fetal hNav1.5e was shifted by 7mV towards
depolarized potential compared with the control adult hNav1.5
form (Fig. 5d and Supplementary Table 2). This shift is consistent
with the shift observed previously in transfected mammalian
cells39–41, thus validating our approach in Xenopus oocytes. To
better reproduce the situation observed in DM, we injected in
Xenopus oocytes an equimolar mix of DM (hNav1.5e, fetal exon
6A) and control (hNav1.5, adult exon 6B) RNA isoforms of
SCN5A. Importantly, this mix of splicing forms also presented a
signiﬁcant shift of steady-state activation towards depolarized
potentials by 3.8mV, compared with the control hNav1.5 form
(Fig. 5d, Supplementary Table 2). Correspondingly, a similar shift
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and DM2 individuals. Molecular size marker is indicated in bp. (d) Graphical representation of RT–PCR analysis depicting the percentage of SCN5A mRNA
including exon 6A in left ventricular heart samples from fetal and adult control, ALS, DCM, DMD, CDM1 and adult DM1 and DM2 individuals. (e) Graphical
representation of quantitative real-time RT-qPCR depicting the mRNA expression of SCN5A relative to RPLP0 in control normal adults (n¼ 5) versus adult
DM1 (n¼ 5) heart samples. Bars indicate s.e.m. bp, base pairs.
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was observed for the time constant of inactivation (Fig. 5e).
Consistent with previous electrophysiological studies39–41, no
signiﬁcant differences were observed between hNav1.5 and
hNav1.5e regarding steady-state inactivation and recovery from
inactivation (Fig. 5f,g). Overall, our results are consistent with
previous studies39–41, and demonstrate that hNav1.5e, the splicing
form of SCN5A expressed in DM and containing the fetal exon
6A, presents a reduced excitability compared with hNav1.5, which
is the adult control SCN5A isoform containing exon 6B.
Alteration of SCN5A splicing leads to heart conduction defects.
Misregulation of the alternative splicing of SCN5A in DM is one
alteration identiﬁed among many others, thus questioning the
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contribution of SCN5A misregulation to the cardiac symptoms
observed in DM. To test the physiological importance of SCN5A
splicing misregulation, we artiﬁcially forced the switch from adult
exon 6B towards fetal exon 6A into wild-type adult mouse heart
using an exon-skipping strategy (Fig. 6a). To insure efﬁcient
transduction of the cardiac muscle and continuous expression
of nuclear antisense oligonucleotides, we engineered and
produced adeno-associated virus (AAV2/9) expressing optimized
U7-snRNA fused to Scn5a antisense sequences (U7-ASScn5a).
Splicing analysis revealed that combination of two U7-AS
constructs, spanning intron 6/exon 6B junction and exon
6B of Scn5A, promoted a switch from inclusion of adult exon
6B towards inclusion of the fetal exon 6A (Supplementary
Fig. 4A). Thus, AAV2/9 expressing both U7-AS constructs
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(AAV-U7-ASScn5a) were injected systemically into newborn
wild-type mice and cardiac functions were investigated 4 and 6
months post injection. Control animals injected either with saline
or empty AAV2/9 presented no splicing alterations of Scn5a and
normal cardiac functions. In contrast, mice injected with AAV-
U7-ASScn5a presented a decreased inclusion of adult exon 6B with
a concomitant 30–40% increase of the inclusion of exon 6A, thus
reproducing the situation observed in DM (Fig. 6b). Quantitative
RT–PCR demonstrated no changes in the expression of Scn5a
mRNA or of its associated subunit Scn1b between control-
and AAV-U7-ASScn5a-injected mice (Fig. 6c). Importantly,
AAV-U7-ASScn5a-injected mice reproduce some of the key
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pathological features of DM, including conduction defects and
heart arrhythmias. Indeed, ECG performed 4 months post
injection revealed a signiﬁcant prolongation of the PR intervals
(Student t-test, P value r0.001) in AAV-U7-ASScn5a-injected
mice compared with control injected mice (Fig. 6d,e). In contrast,
QT interval was not signiﬁcantly altered, and we identiﬁed only a
trend towards increased QRS duration (Student t-test, P value of
0.058 with 8 AAV-U7-ASScn5a-injected mice on 25 presenting a
QRS higher than 19ms versus 16.5ms in control mice) (Fig. 6e
and Supplementary Fig. 4B). Similarly, analysis of heart functions
in 6-month-old animals showed that AAV-U7-ASScn5a-injected
mice present a consistent increase of the PR interval compared
with control injected mice (40.5ms versus 34.8ms respectively;
Student t-test, P value r0.05), without signiﬁcant changes of
the QRS and QT intervals (Supplementary Fig. 4B). Of interest, a
similar elongation of the PR interval was observed in Scn5aþ /
mice, which are hemizygote for Scn5a expression and represent
an established model for cardiac-conduction disease45–47.
Furthermore, ECG analyses also revealed that 44% of
AAV-U7-ASScn5a-injected mice develop signiﬁcant (Student
t-test, Po0,001) heart arrhythmia at 4 months post injection
with an average of ﬁve arrhythmic events, deﬁned as variation of
the RR interval, per minute whereas control injected animals
showed no alterations (Fig. 6f,g). We did not detect
ventricular ﬁbrillations or second and third-degree heart
blocks in any injected animals. In contrast, we observed
supraventricular premature contractions and atrial ﬁbrillation in
AAV-U7-ASScn5a-injected mice (Fig. 6f), and ﬁve of these
injected mice died suddenly between 4 and 6 months post
injections (none of the control mice died). These electrical
alterations were speciﬁc and not caused by global cardiac
remodelling since we observed neither systolic nor diastolic
alterations by doppler echocardiography (Supplementary Table 3)
and no change in heart/body weight ratio (4.4±0,1mg g 1
in control, n¼ 9, versus 4,7±0,2mg g 1 in AAV-U7-ASScn5a-
injected animals, n¼ 14). As further control, H&E-staining
revealed normal heart structures with no evident
cardiomyopathy or dilation at 6 months post AAV injections
(Supplementary Fig. 4C). Similarly, quantitative RT–PCR
experiments show no alteration in the expression levels of
Nppa, Nppb (encoding Anp and Bnp, respectively) and
Myh7 mRNAs (Supplementary Fig. 4D), suggesting no overt
cardiac remodelling in antisense AAV-U7-ASScn5a-injected mice.
Moreover, Sirius Red staining conﬁrmed normal heart structures
but also revealed some mild ﬁbrosis (Fig. 6h), which was
conﬁrmed by increased expression of collagen Cola1a and Tgfb1
mRNAs (Fig. 6i). Interestingly, mild ﬁbrosis is also observed in
DM cardiac samples17,18, as well as in individuals and mice
models with loss-of-function mutations of the SCN5A
gene20,21,46,47. Overall, heart arrhythmias and prolonged PR
interval in AAV-U7-ASScn5a-injected animals demonstrate that
inclusion of the fetal exon 6A of Scn5a is inappropriate to adult
mouse heart physiology. However, while we found a clear
elongation of the PR interval, we did not detect a signiﬁcant
alteration of the QRS duration as only a third of AAV-U7-
ASScn5a-injected mice present increased QRS duration (419ms).
Interestingly, similar ﬁndings have been described in Scn5aþ /
mice, which all show elongation of the PR interval, while only a
subset of Scn5aþ / animals present a prolongation of the QRS
interval45. Hence, elongation of the PR interval is not
systematically associated with increased duration of the QRS in
mouse model of Scn5a dysfunction. Thus, to strengthen our data,
we mathematically tested whether human cardiac parameters
would be altered by the electrophysiological differences caused by
the switch from adult exon 6B towards fetal exon 6A of SCN5A.
Simulation based on a modiﬁed O’Hara-Rudy model48,49
predicted a change of the QRS duration from 72ms with
control adult hNav1.5 to 88ms with fetal hNav1.5e, hence a 22%
increase (Fig. 7a and Supplementary Fig. 5). Furthermore, we also
tested extent of atrio-ventricular change50. Mathematical
simulation predicted a change of the atrium-His interval from
81ms with control hNav1.5 to 143ms with fetal hNav1.5e
(Fig. 7b). Overall, these results support our mouse results and
provide additional evidences that misregulation of SCN5A
alternative splicing causes cardiac-conduction abnormalities,
which is a key pathological feature of DM (Fig. 7c).
Discussion
Cardiac defects affect 80% of individuals with DM and represent
the second most common cause of death in this disease17,18.
However, the molecular mechanisms responsible for
cardiac-conduction delay and ventricular tachycardia in DM are
unclear. Using RNA sequencing we identiﬁed various novel
splicing misregulation events in DM1 heart samples. Among
these changes, the splicing switch from adult exon 6B to fetal
exon 6A in SCN5A mRNA is of particular interest. Previous
studies39–41 as well as ours indicate that hNav1.5e, the splicing
variant of SCN5A found in DM and that contains the fetal exon
6A, possesses a reduced excitability compared with the normal
adult splicing form of SCN5A containing the exon 6B.
Consequently, the switch from the hNav1.5 to the hNav1.5e
channel in DM may cause a slower upstroke velocity of the
cardiac action potential, leading to conduction slowing.
Importantly, this hypothesis is supported by mathematical
simulation as well by animal model, since imposing a switch
from inclusion of the control adult exon 6B towards using the
fetal exon 6A of Scn5A in adult mouse heart led to
cardiac-conduction delay and heart arrhythmias, two key
features of DM. Moreover, clinical evidence also supports an
alteration of the sodium current in DM. Indeed, the
electrophysiological features39–41 of the fetal isoform of SCN5A
expressed in DM are similar to the electrophysiological
characteristics observed with loss-of-function mutations of
SCN5A causing cardiac-conduction disease51–53. Also, there are
some similarities of ECG recording, including prolongation of the
PR interval and of the QRS duration, between individuals with
DM and individuals affected by cardiac-conduction disease
caused by loss-of-function mutations in SCN5A42,54. Finally, the
induction of abnormal ECG pattern in DM patients treated with
ajmaline55,56, a class Ia antiarrhythmic agent acting on the cardiac
sodium channel and the abnormal sodium current observed in a
mouse model of DM57, are also evocative of a dysfunction of the
sodium channel in DM. Overall, our results suggest that
misregulation of the splicing of SCN5A participates in a subset
of electrical cardiac alterations observed in DM, namely the
cardiac-conduction delay and the heart arrhythmias. However, it
is likely that other alternative splicing alterations and/or
mechanisms58–61 are participating to the full pattern of cardiac
alterations in DM since knockout of Mbnl1 and Mbnl2 in mice
leads to only mild alteration of Scn5A splicing, while these mice
show severe conduction disease and cardiac dilatation43,44.
In conclusion, this work may also have some clinical
importance such as considering with caution the treatments of
DM patients with pharmaceutical agents that reduce the activity
of the cardiac sodium channel, including mexiletine, ﬂecainide
and other antiarrhythmic drugs of class I. In that aspect, this
study may provide a molecular explanation to the adverse cardiac
reaction of some patients with myotonic dystrophic to treatment
with drugs reducing activity of SCN5A (refs 62,63). Involvement
of the cardiac sodium channel in DM might also highlight the
importance of considering polymorphism in the SCN5A gene, as
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well as in other genes such as SCN10A, as a possible cause of the
clustering of cardiac alterations in some families of DM64, an
hypothesis supported by the recent report that DM exacerbates
Brugada syndrome caused by a mutation in SCN5A (ref. 65).
Inversely, it remains to be tested whether mutations in intronic
regions regulating alternative splicing of SCN5A exon
6A/6B might be considered as a cause of cardiac-conduction
abnormalities in patients in whom no mutations were identiﬁed
in the coding sequence of SCN5A. Also, if dysfunction of the
cardiac sodium channel in DM is comparable in some aspects to
cardiac-conduction disease caused by mutations in SCN5A, an
attractive supposition would be that therapeutic approaches
developed for these diseases could be considered for DM. Finally,
if cardiac-conduction defects in DM are associated with an
alteration of the alternative splicing of SCN5A, one may hope
that correction of splicing misregulations through approaches
releasing MBNL1 from CUG expanded repeats or through
approaches reducing the expression of pathogenic CUG
RNA66,67 may alleviate the cardiac symptoms of DM.
Methods
Human samples. All samples were heart left ventricles that were sampled with the
informed consent of individuals and approved by the Institutional Review Board of
the Pitie´-Salpeˆtrie`re hospital, of the Neuromuscular Research Center of the Tam-
pere University Hospital, of the Hospital Donostia and of the Toneyama National
Hospital. Non-affected heart samples (CTL #1 to #3) were purchased at Ambion
and Stratagene, respectively. DCM #1 and #2 were patients suffering from DCM of
uncharacterized genetic origin. DMD #1 to #4 were patients affected with DMD.
ALS #1 to #3 were patients with ALS described previously68. DM1 samples #1 and
2 3 4 5 61 2 3 4 5 61 2 3 4 5 61 2 3 4 5 61
I II III IV
2 3 4 5 61 2 3 4 5 61 2 3 4 5 61 2 3 4 5 61
I II III IV
Adult
5 76A 6BMBNL1
– +
5 76A 6BMBNL1
MBNL1
MBNL1
MBNL1
MBNL1
Fetal
hNav1.5e hNav1.5e
Endo M
Epi
ECG
APs
hNav1.5e
hNav1.5
APs
Control Myotonic dystrophy
Conduction delay and heart arrhythmiaNormal adult heart conduction
hNav1.5 hNav1.5e
200 ms
hNav1.5
hNav1.5e
200 ms
Nodal-His
Atrium
10
0 
m
V
a b
c
UG
CUG
CUG
CUG
CUG
CU
G
CU
G
CU
G
C
U
G
C U G
C
Figure 7 | Computer simulation predicts cardiac conduction abnormalities in DM. (a) Simulations of ECG (upper) and action potential (AP) alterations
(middle and lower) caused by the switch from adult SCN5A exon 6B towards fetal exon 6A, using a modiﬁed human ventricular ORd model. (b) Simulations
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2 were from cardiac transplantation for end stage heart failure with conduction
system disease in a 45-year-old male and a 48-year-old female suffering from DM1.
DM1 patient #3 is a 58-year-old female with 500 CTG repetitions in blood. DM1
patients #4 to #6 have been described previously68 with expansion of 4,300 (female,
58 years); 4,800 (male, 63 years); 5,800 (female, 56 years); andB6,000 CTG repeats
in heart. DM1 samples #7 to #9 were patients with BAV1 and sadly unknown
number of CTG repeats. DM2 patients #1 to 4 were described previously69,70. DM2
patients #5 heart sample was obtained at immediate autopsy after sudden bilateral
renal thrombosis at the age of 71 years. He had B4,800 CCTG repeats in
leucocytes.
mRNA sequencing. RNA sequencing was performed on DM1 samples #4 to #6
described previously68. After isolation of total cellular RNA from human heart
samples, libraries of template molecules suitable for high throughput DNA
sequencing were created using ‘TruSeq RNA Sample Preparation v2 Kit’ (Illumina).
Brieﬂy, mRNA was puriﬁed from 1 mg total RNA using poly-T oligo-attached
magnetic beads and fragmented using divalent cations at 94 C for 8min. The
cleaved mRNA fragments were reverse transcribed to cDNA using random primers
then the second strand of the cDNA was synthesized using DNA Polymerase I and
RNase H. The double-stranded cDNA fragments were blunted using T4 DNA
polymerase, Klenow DNA polymerase and T4 PNK. A single ‘A’ nucleotide was
added to the 30 ends of the blunt DNA fragments using a Klenow fragment
(30- to 50-exo minus) enzyme. The cDNA fragments were ligated to double-
stranded adapters using T4 DNA Ligase. The ligated products were enriched by
PCR ampliﬁcation (30 s at 98 C; (10 s at 98 C, 30 s at 60 C, 30 s at 72 C)  12
cycles; 5min at 72 C). Then surplus PCR primers were removed by puriﬁcation
using AMPure XP beads (Agencourt Biosciences Corporation). DNA libraries were
checked for quality and quantiﬁed using 2100 Bioanalyzer (Agilent). The libraries
were loaded in the ﬂow cell at 7pM concentration and clusters were generated in
the Cbot and sequenced in the Illumina Hiseq 2000 as paired-end 2 100 base
reads. FASTQ ﬁles were generated with CASAVA v1.8.2.
Bioinformatic analysis. A total of 1.857.442.522 short reads were mapped onto
the human genome (hg19 assembly) by using Tophat2 software71 (release v2.0.5)
with a mapping rate ranging from 83 to 90%. Htseq-count (release 0.5.3p3). The
Cufﬂinks software72 (release 2.0.2) was used to call the gene expression level
according to the ensembl gene annotation (release 66). DEXseq software22 (release
v1.4.0) was then used to identify differential exons usage and signiﬁcant over and
under-expressed genes were selected by using Benjamini & Hochberg adjusted
P value (FDR r0.1).
Computer simulation of action potential durations and ECG. Two mathematical
models, O’Hara-Rudy (ORd) dynamic model48,49 of ventricular myocytes and
rabbit atrio-ventricular node model50, were employed to simulate action potential
of cardiac cells and ECG. For the simulation, parameters of the activation gates for
control hNav1.5, an equimolar mix of hNav1.5 and hNav1.5e, and hNav1.5e were
estimated to match the experimental data obtained with Xenopus oocytes. Na
currents and curves of voltage dependence of control hNav1.5, an equimolar mix of
hNav1.5 and hNav1.5e, and hNav1.5e were reconstructed using these estimated
parameters (Supplementary Fig. 5A–D). The parameters for the inactivation gate
were unchanged. To get ECG similar to the left precordial ECG, a unipolar
recording electrode was located 2.6 cm far from the epicardial border of the
ventricular wedge preparation model (Supplementary Fig. 5E). The model consists
of endocardial (Endo), midmyocardial (M) and epicardial (Epi) layers of
thicknesses 0.12, 0.65 and 0.24 cm, respectively. The membrane kinetics and the
transmural heterogeneity were based on the ORd model48 with twice sodium
channel conductance to reproduce physiological ranges of both ventricular
conduction velocity (B60 cm s 1 along the ﬁbre) and tissue excitability.
The pacing stimuli of 2ms and twice diastolic threshold were applied
transmembranously to the part of endocardial border at 1Hz to achieve steady
state. The action potentials of Endo, M and Epi are recorded at the centre of each
myocardial layer. Temperature employed in the simulation was 37 C. Ionic
concentrations employed in the simulation were 96mM NaCl, 2mM KCl, 1.8mM
CaCl2, 1mM MgCl2, 10mM HEPES/KOH and pH 7.4. Other model parameters
and the numerical approach have been described elsewhere49. One-dimensional
mathematical model50 of atrio-ventricular node was employed to simulate the
conduction between atrium to ventricle. Although this model was based on the
experimental data in rabbit heart, this is, in our knowledge, the only model for AV
conduction. The simulation parameters for the equimolar mix of hNav1.5 and
hNav1.5e and hNav1.5e were set to reproduce the shift inactivation and the
decrease of peak Na current observed in oocytes. The multicellular model consisted
of atrium and AV node, and action potentials of atrium and AV node cells were
simulated with the stimulus intervals of 350ms.
Construction and analysis of the SCN5A minigenes. Exons 5, 6A, 6B and 7 were
PCR ampliﬁed from human DNA (Clontech) with FWD primer: 50-aaaagctagcgtac
accttcaccgccatttacacc-30 and REV primer: 50-aaaagcggccgcggatcactgaggtaaaggtcca
gg-30 , and inserted between the NheI and NotI restriction sites of pCDNA3.1þ
(Invitrogen). Mutations in SCN5A intron 5 were introduced by primer-directed PCR
mutagenesis. C2C12 cells plated in 6-well plates were co-transfected with
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions with
SCN5A minigene and DMPKS DT960, V5-CUGBP1, V5-MBNL1 40 kDa
(NM_207292) and siRNA directed against MBNL1 (50-CACGGAAUGUAAAUU
UGCAdTdT-30 ; Eurogentec) or against CUGBP1 (NM_198700; NM_006560;
NM_001025596; NM_001172640; NM_001172639; Thermo Scientiﬁc) in DMEM
medium containing 1 g per l glucose and 2% horse serum (37 C, 5% CO2) during
24h. Total RNAs were extracted using Tri Reagent (MRC) and subjected to reverse
transcription using Transcriptor Reverse Transcriptase kit (Roche). PCR were
performed using Taq polymerase (Roche), one denaturation step at 94 C for 2min,
26 cycles of ampliﬁcation 94 C for 1min, 58 C for 30 s., 72 C for 45 s and a ﬁnal
step at 72 C for 7min using the forward primer (50-cttctgcctgcacgcgttcac-30) and the
reverse (50-acgggccctctagactcg-30) speciﬁc to pCDNA3.1- SCN5A minigene. The
PCR products were digested by BstBI enzyme. PCR products of mRNAs including
exon 6A and 6B are of 116þ 71 bp and 187 bp, respectively. PCR products were
precipitated, analysed by electrophoresis on 6,5% polyacrylamide gel, BET labelled
and quantiﬁed using Typhoon scanner.
Electrophysiological measurements. Ovarian lobes were obtained from Xenopus
laevis under anaesthesia (0.4% 3-aminobenzoic acid ethyl ester) and transferred to
Ca2þ -free Barth medium (84mM NaCl, 1mM, 2.4mM NaHCO3, 0.82mM
MgSO4 and 7.5mM Tris/HCl pH 7.4). Oocytes in stages V and VI were incubated
in Ca2þ -free Barth medium containing 1.2mgml 1 collagenase for 60min.
After washing repeatedly with Barth medium, the oocytes were isolated and
defolliculated mechanically. Plasmids containing cDNAs of hNav1.5 or hNav1.5e
were linearized using the NotI restriction enzyme and in vitro transcribed using the
T7 RNA polymerase. Concentrations of the cRNA variants were adjusted to
B0.002 mgml 1 using the gel documentation system from Herolab (Wiesloch,
Germany) and a reference RNA sample (0.24–9.5 kb RNA ladder, Invitrogen
Life Technologies), before injecting B50–80 nl cRNA per oocyte. After 3 days
incubation at 18 C in Barth medium, the peak current amplitude of the whole-cell
Naþ current was between 0.5 and 7.5 mA, depending on the quality of the oocyte
batch. Cells producing currents larger than 6 mA were not selected for the
evaluation of the channel kinetics. Measurements were performed in totally 11
different batches of oocytes. Whole-cell Naþ currents were recorded with the
two-microelectrode voltage-clamp technique using the TEC-05-S ampliﬁer
(npi electronic GmbH, Tamm, Germany) and the following bath solution (96mM
NaCl, 2mM KCl, 1.8mM CaCl2, 1mM MgCl2, 10mM HEPES/KOH and pH 7.4).
Currents were elicited by test potentials from  80 to 20mV in 5 or 10mV
increments at a pulsing frequency of 1.0 Hz (holding potential  120mV).
Steady-state activation (mN) was evaluated by ﬁtting the Boltzmann equation
mN¼ {1þ exp[ (VVm) per s]} 1 to the normalized conductance as
function of voltage, where V is the test potential, Vm the mid-activation potential,
and s the slope factor in mV. Recording and analysis of the data was performed on
a personal computer with the ISO3 software (MFK, Niedernhausen, Germany).
The sampling rate was 50 kHz. Student´s t-test was used to test for statistical
signiﬁcance. Statistical signiﬁcance was assumed for Po0.05.
In vivo gene transfer. All mouse procedures were done according to protocol
approved by the Committee on Animal Resources at the Centre d’Exploration
Fonctionnelle of UPMC animal facility and under appropriate biological
containment. AAV2/9 vectors expressing Scn5a antisense sequences driven by an
optimized U7-snRNA (U7-AS) construct described previously73 were produced by
co-transfection in HEK293 cells of pAAV2(U7-AS), pAD-DELTA-F16 encoding
adenovirus helper functions and p5E18-VD2/9. Vector particles were puriﬁed on
iodixanol gradients from cell lysates obtained 72 h after transfection, and titres were
measured by RT-qPCR. The vector preparation used in this study had a titer of
1 10EXP13 vector genomes (vg) ml–1. U7-AS constructs that contain antisense
sequences to target intron 6/exon 6B border or exon 6B of Scn5A were cloned in
the same AAV backbone. 2 days old C57BL/6 mice were injected in the temporal
vein for systemic delivery with 50 ml of either with saline, empty AAV2/9 or
AAV2/9-U7-AS (1 1012 vector genomes ml 1). Six months after injections, mice
were killed, hearts were collected and snap-frozen in liquid nitrogen-cooled
isopentane and stored at  80 C.
ECG recordings and echocardiographic examination. Mice were anaesthetized
with isoﬂurane and surface ECG was recorded using 23-gauge, subcutaneous
needle electrodes (Gould Instrument Systems), afﬁxed to each limb. ECG was
continuously monitored for 3min (software IOX 2, EMKA Technologies, Paris
France). Heart rate, PR and QRS duration were measured from recording traces
using ECG auto V.1.5.7 software (Emka Technologies). Non-invasive measure-
ments of left ventricular dimensions were evaluated under isoﬂurane anaesthesia,
using echocardiography-Doppler (General Electric Medical systems Co, Vivid 7
Dimension/Vivid 7 PRO) with a probe emitting ultrasounds with 9–14MHz
frequency. The two-dimensionally guided Time Motion mode recording of the left
ventricle provided the following measurements: diastolic and systolic septal
and posterior wall thicknesses, internal end-diastolic and end-systolic diameters,
ejection fraction, fractional shortening of left ventricular diameter. Each set of
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measurements was obtained from a same cardiac cycle. At least three sets of
measures were obtained from three different cardiac cycles.
Recombinant protein production and puriﬁcation. Escherichia coli BL21(RIL)
pRARE competent cells (Invitrogen) were transformed with peGEX-MBNL1D101,
which is a C-terminal truncated form of MBNL1 with higher solubility but
identical afﬁnity than MBNL1 full-length, (gift from Prof. C. Branlant), grown at
37 C in 400ml of LB medium supplemented with Kanamycin until OD600¼ 0.5,
0.5mM IPTG was added and the culture was further incubated 4 h at 30 C.
Harvested cells were sonicated in 50mM Tris-Cl pH 7.5, 300mM NaCl, 5%
glycerol, 1mM DTT, 5mM EDTA, centrifuged 20min at 20,000g and recombinant
GST-MBNL1D101, protein was puriﬁed using GST-Kits (Novagen) and store in
20% glycerol.
RNA transcription and gel-shift assays. Templates for transcription were
obtained by PCR with pCDNA3.1-SCN5A or pCDNA3.1-SCN5A mutant
minigenes and the primers (FWD that include a T7 promoter sequence: 50-TAA
TACGACTCACTATAGGGCCATGGAACTGGCTGGACTTT-30 and REV:
50-AGAAAGAGAGGGGTGGTCG-30). Transcription reaction was performed
using T7 transcription kit (Ambion) in presence of 1 ml of aP32-CTP (10mCi,
800Ci per mmole, Perkin Elmer), analysed on 8% denaturing polyacrylamide and
quantiﬁed with LS-6500 counter (Beckman). After transcription, 1 unit of DNase I
(Invitrogen, Carlsbad, CA) was added, and the sample was incubated for additional
30min at 37 C. Transcribed RNAs were then puriﬁed by micro Bio-Spin 6
chromatography columns (Bio-rad) according to the manufacturer’s instructions.
The sizes of RNAs were checked by gel electrophoresis on a denaturing 6%
polyacrylamide gel. For gel shift, 1 ml of labelled RNA was annealed in binding
buffer (BB, 50mM Tris-HCl (pH 7.0), 75.0mM NaCl, 37.5mM KCl, 5.25mM
DTT, 0.1mgml 1 BSA, 0.1mgml 1 E. Coli tRNA) at 90 C for 5min. and
allowed to cool to room temperature by placing on a bench top. After cooling,
MgCl2 and RNAsin were added to a ﬁnal concentration of 0.75mM and
0.4U ml 1 respectively. GST-MBNL1-D101 protein was then added to the above
solution and the mixture was incubated at 25 C for 20min. The solution mixture
was loaded onto a non-denaturing 6.0% (w/v) polyacrylamide gel (acrylamide/
bisacrylamide, 40:1, w/w) containing 0.5 TBE (1X TBE is 90mM Tris-base,
89mM Boric acid and 2mM EDTA (pH 8.0)), which had been pre-electrophoresed
at 110V for 20min. at 4 C. The gel was electrophoresed at 110V at 4 C for 3 h.
The gel was then dried and exposed to a phosphorimager screen and imaged using
a Typhoon 9410 variable mode imager. The data were ﬁt to the following equation:
y¼minþ ((maxmin))/(1þ (x/IC50)-HillSlope)), where y is the percentage of
RNA bound to MBNL1, x is the concentration of MBNL1, min and max are the
minimum and maximum percentage of RNA bound to MBNL1 (0–100%) and
IC50 is the concentration where 50% of maximum binding is achieved.
RT–PCR analyzes. Total RNA was isolated by TriReagent (Molecular Research
Center). A total of 1mg of total RNA isolated from heart samples of control or DM
individual was subjected to reverse transcription using random hexanucleotide and
the Transcriptor High Fidelity cDNA synthesis kit (Roche Diagnostics). PCR was
performed with Taq polymerase (Roche), using the following protocol: one dena-
turation step at 94 C for 2min, 30 cycles of ampliﬁcation 94 C for 1min, 60 C for
1min, 72 C for 2min and a ﬁnal step at 72 C for 5min using primers described in
the Supplementary Table 4. The PCR products were precipitated, analysed by
electrophoresis on a 6.5% polyacrylamide gel, stained with ethidium bromide and
quantiﬁed using a PhosphorImager Typhoon scanner (GE Healthcare) and the
ImageQuaNT software. Concerning analysis of alternative splicing of human
SCN5A, the forward primer was located within SCN5A exon 5 (FWD: 50-CTTCT
GCCTGCACGCGTTCAC-30) and the reverse primer within SCN5A exon 7
(REV: 50-CAGAAGACTGTGAGGACCATC-30). Since SCN5A exons 6A or 6B are
of similar size (92 nts), PCR products were digested by BstBI enzyme before loading
on 6.5% polyacrylamide gel, resulting in PCR products of 240 bp (exon 6B) and a
doublet of 115 bp and 125 bp (exon 6A digested by BstBI).
Quantitative real-time PCR analyzes. Total RNA was isolated by TriReagent
(Molecular Research Center). cDNAs were generated using using the Transcriptor
High Fidelity cDNA synthesis kit (Roche Diagnostics). Real-time qPCR were
realized using the LightCycler 480 SYBR Green I Master (Roche) in a Lightcycler
480 (Roche) with 15min at 94 C followed by 50 cycles of 15 s at 94 C, 20 s at
58 C and 20 s at 72 C using primers described in the Supplementary Table 5.
Rplpo mRNA was used as standard and data were analysed using the Lightcycler
480 analysis software (2DCt method).
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